The survival time of NSCLC patients with the overexpression of LIMD2 was shorter than that of patients with lower expression, indicating that LIMD2 may serve as a therapeutic target in NSCLC (Zhang et al., 2019). The gene discussed is LIMD2; the disease is non-small cell lung carcinoma.